Why the study?
Ovarian function suppression combined with tamoxifen or an aromatase inhibitor suppresses circulating oestradiol, which could have adverse cardiovascular and metabolic effects and increase cardiovascular disease risk.
Does ovarian function suppression in combination with tamoxifen or an aromatase inhibitor increase cardiovascular and metabolic adverse events in premenopausal women with early estrogen receptor-positive breast cancer?
Does ovarian function suppression in combination with tamoxifen or an aromatase inhibitor increase cardiovascular and metabolic adverse events in premenopausal women with early estrogen receptor-positive breast cancer?
The addition of ovarian function suppression to tamoxifen in premenopausal women with early breast cancer significantly increases the risk of hypertension and hyperglycaemia, highlighting the need for baseline cardiometabolic risk assessment and monitoring.
May warrant cardiometabolic monitoring with tamoxifen plus OFS; extends adverse-event data from endocrine therapy trials in premenopausal women.
Introduction: Adjuvant endocrine therapy is a key treatment in oestrogen receptor positive early breast cancer (BC). For premenopausal women, ovarian function suppression (OFS) in combination with either tamoxifen or aromatase inhibitor (AI) is utilised in high-risk cases. The resultant suppression of circulating oestradiol from OFS could have adverse cardiovascular and metabolic effects, subsequently increasing the risk of cardiovascular disease. Material and methods: A systematic search of online databases was conducted to identify randomised control trials involving OFS which reported cardiovascular and metabolic adverse events. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Results: = 0.03). Conclusions: Our study highlights the potential cardio-metabolic impact of endocrine therapy and OFS on premenopausal women with BC. It also highlights the pressing need for standardisation of routine collection and recording of cardiometabolic history and risk factors as part of baseline assessment and adverse event reporting to better understand the cardiometabolic impact these treatments have on our patients. Further studies, with particular focus on baseline and subsequent development of cardiovascular risk factors, are needed to explore the impact of these drugs on the cardiovascular health of young women with BC.
No takes yet. Share an insight, caveat, or question.
Gue et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: